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Summary Postmarketing data about the effectiveness of zonisamide in childhood
epilepsy was collected from 759 children with various forms of epilepsy (ages 3
months—15 years) to compare the long-term efﬁcacy of zonisamide in the treat-
ment of epilepsy in intellectually normal versus intellectually disabled children. The
follow-up period was 6 months—3 years; 291 children (245 intellectually normal, 46
intellectually disabled) received zonisamide as monotherapy. The remaining patients
received additional antiepilepsy drugs (AEDs); mean numbers of additional AEDs were
1.6 and 2.9 for intellectually normal and intellectually disabled groups, respectively.
Effectiveness could not be evaluated in 30 of the 759 patients because of very rare
or irregular seizure frequency. In the 729 patients evaluated, 78% of intellectually
normal patients and 43% of intellectually disabled patients showed ≥50% reduction
in the number of seizures (P < 0.001). Improvement rates seen in the intellectually
normal group were almost the same for patients with generalized (82%) and partial
(77%) epilepsies, whereas in the intellectually disabled group, the improvement rate
was higher for partial (50%) than generalized (36%) epilepsies (P < 0.01).
These results are consistent with the known phenomenon that intellectually dis-
abled children are likely to have more intractable seizures than children with normal
intelligence.
© 2004 Published by Elsevier Ltd on behalf of BEA Trading Ltd.
Introduction
Zonisamide is a new drug with broad-spectrum
antiepilepsy activity against partial as well as gen-
eralized seizures. The drug has been commercially
licensed in Japan since 1989. Before licensure,
randomized, controlled trials of zonisamide were
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performed by 4 authors;1—4 3 studies were of treat-
ment in adults,1—3 and 1 study examined pediatric
treatment.4 The observation period of these studies
was 12—16 weeks in adults, and 8 weeks in children.
All studies were conﬁned to zonisamide treatment
of generalized seizures. Postmarketing research,
performed at 25 institutions over a 5-year period,
investigated the clinical effectiveness and safety of
zonisamide for the treatment of childhood epilepsy.
The purpose of this postmarketing study was to
compare the long-term efﬁcacy of zonisamide in
the treatment of epilepsy in intellectually nor-
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mal children to that in intellectually disabled
children.
Methods
Patients and study design
A total of 759 patients were included in the study.
All were under 15 years of age. Ages of patients
distributed as follows: less than 1 year, 20 patients
(3%); 1—5 years, 213 patients (28%); 6—10 years,
282 patients (37%); and 11—15 years, 244 patients
(32%). Of the study subjects, 418 were evaluated
as intellectually normal, and 341 were intellectu-
ally disabled, with scores less than 50 based on
their intelligent quotient (IQ) or development quo-
tient (DQ). The IQ was evaluated by Tanaka-Binet
method (Japanese edition of the Stanford-Binet In-
telligence Scale), and in a few cases, by Wechsler
Intelligence Scale for Children–—Revised. The DQ
was evaluated by the Tsumori-Inage method and
Enjoji method (both are evaluated by interview-
ing parents, similar to the Denver Developmental
Screening Test). The observation period of the
study was between 6 months and 5 years.
Overall improvement in seizure control was eval-
uated in both the intellectually normal and the
intellectually disabled groups. In the intellectually
normal group, approximately 15% of patients had
temporal lobe epilepsy and approximately 55% had
non-temporal lobe epilepsy. Generalized epilep-
sies were found in less than 20% of this group. In
contrast, in intellectually disabled patients, ap-
proximately 7% had temporal lobe epilepsy and 35%
non-temporal lobe epilepsy. Generalized epilepsy
was found in almost one-half of this study group’s
subjects.
A total of 729 patients out of the initial 759 pa-
tients were included in the ﬁnal evaluation. Thirty
patients were eliminated from analysis because of
loss to follow-up due to adverse effects, change
of address, too few seizures to evaluate, or other
reasons. Of the intellectually normal group, 401
patients completed the study; of the intellectually
disabled group, 328 completed the study (Table 1).
Table 1 Number of patients (ﬁnal evaluation).
Epilepsies Total
Generalized Partial Unclassiﬁed
Intellectually normal 67 331 3 401
Intellectually disabled 152 170 6 328
Total 219 501 9 729
Thirty patients were excluded because of interruption of follow-up by adverse effects, changes of address, etc.
Table 2 Number of AEDs.
Number of AEDs Number of
patients
Intellectually normal (mean 1.6)
Zonisamide monotherapy 245 (61%)
2 AEDs 112 (28%)
3 AEDs 44 (11%)
4 AEDs 12 (3%)
Intellectually disabled (mean 2.9)
Zonisamide monotherapy 46 (14%)
2 AEDs 67 (20%)
3 AEDs 128 (39%)
4 AEDs 64 (20%)
5 AEDs 32 (10%)
Evaluation of safety and efﬁcacy
The efﬁcacy of zonisamide in the treatment of
seizures was evaluated on the basis of improve-
ment over a minimum 5-month period of observa-
tion following the initiation of treatment. Patients
who were observed less than 5 months were not in-
cluded in the efﬁcacy analysis. Statistical analysis
was performed using the chi-square method. Doses
of zonisamide varied from 2mg/kg per day to more
than 10mg/kg per day, and about 70% of patients
received 2—8mg/kg per day of zonisamide.
Zonisamide was regarded as effective for seizure
control if the seizure frequency was reduced by
≥50% compared to baseline seizure frequency
measured before treatment began. The improve-
ment rate was deﬁned as the percentage of the
total number of patients meeting this efﬁcacy
standard. Adverse effects were recorded for all
patients.
Sixty-one percent of the patients in the intellec-
tually normal group were treated with zonisamide
monotherapy (Table 2). Twenty-eight percent of
the patients were treated with zonisamide and 1
other antiepilepsy drug. In contrast, zonisamide
monotherapy was given to only 14% of the patients
in the intellectually disabled group. Zonisamide
was given together with 2 other antiepilepsy drugs
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in 39% of this group’s patients. The mean num-
ber of AEDs, including zonisamide, was 1.61 in the
intellectually normal group and 2.94 in the intel-
lectually disabled group.
Results
Efﬁcacy
The overall improvement rating for generalized
seizures is shown in Table 3. The characteristics
of the seizures were different for the 2 groups.
Generally speaking, improvement was signiﬁcantly
beneﬁcial for persons of normal intelligence (80%,
P < 0.001), notably for tonic (89%, P < 0.001), and
generalized tonic—clonic seizures (87%, P < 0.01),
as well as other seizure types (80%, P < 0.05). For
all categories of partial seizures, the improvement
Table 3 Overall improvement rating: generalized
seizures.
Seizure type Improved (reduction ≥50%
of seizure frequency)
Intellectually
normal
Intellectually
disabled
Absence 3/4 (75%) None
Atypical absence 4/8 (50%) 6/19 (32%)
Myoclonic seizure 3/6 (50%) 23/43 (53%)
Tonic seizure 16/18 (89%)*** 28/77 (36%)
GTC 26/30 (87%)** 21/37 (57%)
Others 19/23 (83%)* 14/28 (50%)
Total 71/89 (80%)*** 92/204 (45%)
∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 between the
intellectually normal and the intellectually dis-
abled groups, respectively; GTC = generalized tonic—
clonic.
Table 5 Overall improvement rating.
Syndrome Improved Unimproved Total
Intellectually normal Generalized 55 (82%)*** 12 (18%) 67 (100%)
Partial 256 (77%) 75 (23%) 331 (100%)
Unclassiﬁed 3 (100%) 0 (0%) 3 (100%)
Total 314 (78%)*** 87 (22%) 401 (100%)
Intellectually disabled Generalized 54 (36%) 98 (64%) 152 (100%)
Partial 85 (50%) 85 (50%) 170 (100%)
Unclassiﬁed 2 (33%) 4 (67%) 6 (100%)
Total 141 (43%) 187 (57%) 328 (100%)
*** P < 0.001 between the intellectually normal and the intellectually disabled groups.
Table 4 Overall improvement rating: partial
seizures.
Seizure
type
Improved (reduction ≥50%
of seizure frequency)
Intellectually
normal
Intellectually
disabled
SPS 73/89 (82%)*** 27/39 (69%)
CPS 146/170 (86%)*** 74/123 (60%)
SGS 131/150 (87%)*** 70/103 (68%)
Others 11/13 (85%)*** 3/5 (60%)
Total 361/422 (86%)*** 174/270 (64%)
SPS = simple partial seizure; CPS = complex partial
seizure; SGS = secondarily generalized seizure.
*** P < 0.001 between the intellectually normal and
intellectually disabled groups.
rating was signiﬁcantly higher (P < 0.001) in the
intellectually normal group (86%) than in the intel-
lectually disabled group (64%) (Table 4).
Table 5 compares the improvement rating accord-
ing to the classiﬁcation of epilepsy syndromes. The
improvement rating was higher (P < 0.001) in the
intellectually normal group (78%) than in the in-
tellectually disabled group (43%). In the intellectu-
ally disabled group, patients with partial epilepsy
showed a slightly better response than those with
generalized epilepsy (50% versus 36%, P < 0.01).
Table 6 shows the improvement rating for pa-
tients with various types of generalized epilepsies.
Primary generalized epilepsy was better controlled
by zonisamide (P < 0.001) in intellectually nor-
mal patients (91%) than in intellectually disabled
patients (58%). The improvement rating data for
partial epilepsies is shown in Table 7. Only tem-
poral lobe epilepsy did not show a signiﬁcant dif-
ference in the improvement rating between the 2
groups.
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Table 6 Overall improvement rating: generalized epilepsies.
Epilepsies Improved Unimproved Total
Intellectually normal PGE 43 (91%)*** 4 (9%) 47 (100%)
West syndrome 1 (100%) 0 1 (100%)
LGS 3 (50%) 3 (50%) 6 (100%)
Other SGE 5 (56%) 4 (44%) 9 (100%)
Unclassiﬁed GE 3 (75%) 1 (25%) 4 (100%)
Total 55 (82%)*** 12 (18%) 67 (100%)
Intellectually disabled PGE 11 (58%) 8 (42%) 19 (100%)
West syndrome 7 (33%) 14 (67%) 21 (100%)
LGS 7 (21%) 26 (79%) 33 (100%)
Other SGE 26 (40%) 39 (60%) 65 (100%)
Unclassiﬁed GE 3 (21%) 11 (79%) 14 (100%)
Total 54 (36%) 98 (64%) 152 (100%)
PGE = primary generalized epilepsy; LGS = Lennox-Gastaut syndrome; SGE = secondarily generalized epilepsy;
GE = generalized epilepsy.
*** P < 0.001 between the intellectually normal and the intellectually disabled groups.
Table 7 Overall improvement rating: partial epilepsies.
Epilepsies Improved Unimproved Total
Intellectually normal TLE 36 (65%) 19 (35%) 55 (100%)
Non-TLE 177 (79%)*** 47 (21%) 224 (100%)
Others 43 (83%)*** 9 (17%) 52 (100%)
Total 256 (77%)*** 75 (23%) 331 (100%)
Intellectually disabled TLE 12 (50%) 12 (50%) 24 (100%)
Non-TLE 61 (51%) 59 (49%) 120 (100%)
Others 12 (46%) 14 (54%) 26 (100%)
Total 85 (50%) 85 (50%) 170 (100%)
TLE = temporal lobe epilepsy.
*** P < 0.001 between the intellectually normal and the intellectually disabled groups.
Table 8 shows the relationship between im-
provement rates and age of epilepsy onset. In any
age group, the improvement rating was greater
(P < 0.001) in the intellectually normal group (78%)
than in the intellectually disabled group (43%).
Table 8 Overall improvement rating.
Age of onset (years) Improved (reduction ≥50% of seizure frequency)
Intellectually normal Intellectually disabled Total
<1 12/14 (86%) 1/6 (17%) 13/20 (65%)
1—5 60/83 (72%) 52/120 (43%) 112/203 (55%)
6—10 140/170 (82%) 46/100 (46%) 186/270 (69%)
11—15 102/134 (76%) 42/102 (41%) 144/236 (61%)
Total 314/401 (78%)*** 141/328 (43%) 455/729 (62%)
*** P < 0.001 between the intellectually normal and the intellectually disabled groups.
Safety
Adverse effects were experienced by 21% of the
intellectually normal patients, and by 28% of the
intellectually disabled patients (see Table 9). The
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Table 9 Adverse effects of zonisamide.
Patients experiencing
adverse effects (%)
Patients experiencing
no adverse effect (%)
Total
Intellectually normal 86 (21%) 332 (79%) 418 (100%)
Intellectually disabled 96 (28%) 245 (72%) 341 (100%)
Total 182 (24%) 577 (76%) 759 (100%)
Table 10 Adverse effects of zonisamide: monotherapy vs. combination therapy.
Age of onset (years) Zonisamide monotherapy Zonisamide combination therapy Total
<1 2/14 (14%) 3/6 (50%) 5/20 (25%)
1—5 13/71 (18%) 34/142 (24%) 47/213 (22%)
6—10 15/112 (13%) 48/170 (28%) 63/282 (22%)
11—15 14/70 (20%) 53/174 (30%) 67/244 (27%)
Total 44/267 (16%)*** 138/492 (28%) 182/759 (24%)
*** P < 0.001 (monotherapy vs. combination therapy).
incidence of adverse events was slightly higher
in the intellectually disabled group, but there is
no signiﬁcant difference between these groups. In
total, 24% of the 759 patients in this study experi-
enced some adverse effects.
In Table 10, a comparison of adverse events ob-
served with zonisamide monotherapy (16%) versus
combined therapy (28%) demonstrates that fewer
adverse effects were observed in the monotherapy
group (P < 0.001). There were no signiﬁcant differ-
ences in adverse events between age groups, ex-
cept that in the combined therapy group of patients
under 1 year of age, the incidence of adverse ef-
fects was increased (50%).
Discussion and conclusions
Before the commercial licensing of zonisamide
in Japan, a placebo-controlled study in children
showed that the percentage of patients with a
50% or higher decrease in seizure frequency was
50.0% and 43.8%, by zonisamide and valproate,
respectively.4 This study was done by 8 weeks of
observation. Our study of long-term observation
showed that the overall improvement rate was
62%, which was slightly higher than the placebo-
controlled study results. The patients evaluated
before launch had more frequent seizures–—more
than 4 times a month. After commercial licensing,
zonisamide was also administered to many pa-
tients having infrequent seizures. The difference
of the efﬁcacy of zonisamide before and after the
licensure is likely due to the background seizure
frequency of the patients. In intellectually normal
children, the overall improvement rate was thought
to be quite high (78%); furthermore, patients with
generalized epilepsy in the intellectually normal
group showed 82% improvement.
It has generally been thought that zonisamide
is more efﬁcacious for partial epilepsy than gen-
eralized epilepsy.5 It was reported that patients
who had some temporal lobe abnormalities veriﬁed
by EEG, computed tomography, or positron emis-
sion tomography responded well to zonisamide.6 In
that report, zonisamide was effective for partial
epilepsy as well as generalized epilepsy with tem-
poral lobe lesions. In the present study, however,
zonisamide demonstrates efﬁcacy for generalized
epilepsy equal to or greater than its efﬁcacy for par-
tial epilepsy. The patients with generalized epilepsy
who responded well to zonisamide might have had
some temporal lobe abnormalities.
In comparing the efﬁcacy of zonisamide for intel-
lectually normal and disabled patients, zonisamide
was more effective for intellectually normal pa-
tients. In general, intellectually disabled children
have various kinds of central nervous system dis-
turbances. These disturbances relate to the sever-
ity of seizures in epileptic patients with intellectual
disability. However, even for intellectually disabled
patients, zonisamide had good efﬁcacy for seizure
control. Zonisamide can be recommended for the
treatment of both partial and generalized seizures
in intellectually disabled children with epilepsy.
Treatment-emergent adverse effects were ob-
served to have almost the same incidence in the
normal intelligence and the intellectually disabled
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groups. Zonisamide monotherapy demonstrated
less frequent adverse effects than zonisamide
combined therapy. Combined antiepilepsy therapy
often induces adverse effects more frequently in
any antiepilepsy drug, not only zonisamide.7
In the treatment of epileptic children with zon-
isamide, anhidrosis accompanied by elevated body
temperature has been reported, especially during
summer.8,9 Moreover, Shimizu et al. reported a case
of an intellectually disabled 2-year-old boy demon-
strating a heat stroke-like episode associated with
zonisamide treatment.10 This patient showed hy-
perpyrexia and oligohidrosis. In the present study,
cases with anhidrosis were not reported by the
doctors. However, anhidrosis or oligohidrosis is of-
ten difﬁcult to observe, especially by intellectually
disabled patients. Hyperpyrexia and oligohidrosis
should be carefully monitored during zonisamide
treatment.
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